US20080090268A1 - Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method - Google Patents

Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method Download PDF

Info

Publication number
US20080090268A1
US20080090268A1 US11/892,163 US89216307A US2008090268A1 US 20080090268 A1 US20080090268 A1 US 20080090268A1 US 89216307 A US89216307 A US 89216307A US 2008090268 A1 US2008090268 A1 US 2008090268A1
Authority
US
United States
Prior art keywords
blood
diagnostic kit
helicobacter pylori
sample vessels
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/892,163
Inventor
Sitke Aygen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/892,163 priority Critical patent/US20080090268A1/en
Publication of US20080090268A1 publication Critical patent/US20080090268A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia

Definitions

  • the present invention relates to a method for the diagnosis of Helicobacter pylori infection by the oral administration of defined amounts of 13 C-labeled urea and examination for 13 C content of blood samples removed at a defined time.
  • This object is now achieved by removing from 0.1 to 0.6 ml of capillary blood from the finger or ear lobe of a patient or venous blood, in both cases with an empty stomach before the beginning of the test, administering an exact amount of from 10 to 50 mg of 13 C-urea in aqueous solution with a pH value of 2 to 4 to the patient, again removing capillary or venous blood exactly after 10 to 15 min from the administration, and determining the 13 C content of the blood samples by isotope ratio mass spectrometry (IRMS), and deducing the presence of Helicobacter pylori from the increase of the 13 C values.
  • IRMS isotope ratio mass spectrometry
  • the labeled urea is administered in an aqueous solution with a pH value of from 2 to 4.
  • a pH value of from 2 to 4.
  • Citric acid has been found particularly suitable.
  • other organic acids of that kind such as ascorbic acid, are also capable of adjusting the desired pH value. It is also possible to achieve this low pH value by the use of orange juice, grapefruit juice or sour apple juice.
  • the determination of the 13 C content in the blood samples can be effected, for example, by adding a strong non-volatile acid, such as phosphoric acid, which is capable to release the carbon dioxide in a gaseous form from the blood sample, so that it can be measured with an IRMS device.
  • a strong non-volatile acid such as phosphoric acid
  • the method according to the invention is capable of detecting Helicobacter infections when the difference of the 13 C content is as low as 2.0%. It is obvious that the substantially lower amount of the expensive 13 C-urea, on the one hand, and the quickening of the time of the second sampling from 30 min to 10 min are of significant importance to both the patients and the physicians.
  • the removal of a maximum of 0.6 ml of capillary or venous blood is significantly simpler and more convenient than the removal of 3 ml of venous blood in the test of the Metabolic Solutions Inc. As compared to this test, above all, the significantly higher accuracy and precision is of critical importance since the starting value is determined for each patient rather than using the average values, which are accompanied by considerable variations and influenced by the different foods taken up by the subjects.
  • the diagnostic kit according to the invention for performing the method preferably consists of an acidic aqueous solution having a pH value of from 2 to 4 and containing exactly from 10 to 50 mg of 13 C-urea, a patient instruction sheet, two sample vessels for receiving the blood samples, and optionally a blood-sampling device. It is decisive that the kit contains an exaxt amount of 13 C-urea. A kit for children may contain less than for adults in the over all range of 10 to 50 mg 13 C-urea. Also the time difference between the two removals of blood should be exactly measured. Different kits, however, may be run in the over all time range of 10 to 15 min.
  • Another preferred embodiment comprises instead of the ready acidic solution a container for urea with exactly from 10 to 50 mg of 13 C-urea and a pack of a solid pharmacologically acceptable organic acid, such as citric acid.
  • a solid pharmacologically acceptable organic acid such as citric acid.
  • 2 g of citric acid in 200 ml of water or 200 ml of orange juice, grapefruit juice, or sour apple juice is suitable for dissolving from 30 to 50 mg of 13 C-urea.
  • the amount of 13 C-urea can be further decreased down to 10 mg.
  • the blood samples preferably are taken up in commercially available sample vessels for receiving blood samples, for example, Vacutainer®.
  • sample vessels for receiving blood samples for example, Vacutainer®.
  • they may already contain the necessary amount of concentrated phosphoric acid, so that the CO 2 is immediately released from the blood sample.
  • the determination of the 13 C content is then effected by IRMS directly from the gas phase.
  • An increase of the 13 C content of as low as 2% after 10 min indicates infection with Helicobacter pylori.
  • serum may also be withdrawn from the blood sample after a short settling period. All macromolecules and especially the lipids can be removed from this serum sample by ultrafiltration. The remaining liquid is then first subjected to elemental analysis by combustion, and the CO 2 released thereby is again examined by IRMS for the isotope ratio 13 C/ 12 C. In this test method, infection with Helicobacter pylori can be detected at an increase of the 13 C content of as low as from 1 to 1.5%.
  • the blood tests are executed by the physician before and from 10 to 15 min after administration of the 13 C-urea.
  • the Vacutainers® can be collected and sent to a central laboratory where the determination of the 13 C contents is effected. From these results fed-back to the physician, he can diagnose whether or not there is an infection with Helicobacter pylori.
  • the preliminary elemental analysis by combustion can be performed in central laboratories without problems.
  • the recovery of serum from capillary or venous blood and ultrafiltration can be performed without problems at least in clinics.
  • 20 ⁇ l of serum is sufficient and will yield telling results already for an increase of from 1 to 1.5% of 13 C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The method for the diagnosis of Helicobacter pylori infection by the oral administration of defined amounts of 13C-labeled urea and examination for 13C content of blood samples removed at a defined time is effected by a) removing from 0.1 to 0.6 ml of capillary blood from the finger or ear lobe of a patient or venous blood of a patient, in both cases with an empty stomach before the beginning of the test;
  • b) administering an exact amount of from 10 to 50 mg of 13C-urea in aqueous solution with a pH value of 2 to 4 to the patient; c) again removing capillary or venous blood exactly after 10 to 15 min from the administration; and
  • d) determining the 13C content of the blood samples by isotope ratio mass spectrometry (IRMS), and deducing the presence of Helicobacter pylori from the increase of the 13C values.

Description

  • The present invention relates to a method for the diagnosis of Helicobacter pylori infection by the oral administration of defined amounts of 13C-labeled urea and examination for 13C content of blood samples removed at a defined time.
  • The previously usual and, mostly performed method for the diagnosis of Helicobacter pylori infection is the 13C-urea respiration test. This method has been described in detail in EP-A-0 253 927. This test has the disadvantage, that it cannot be applied for children below 3 years and adults suffering from breath in sufficiency like asthma.
  • Rex Moulton-Barrett et al., The American Journal of Gastroenterology, Vol. 88, 1993, pages 369 to 374, describe a method in which 13C-labeled hydrogencarbonate is determined in the serum upon oral administration of 13C-labeled urea. In this test, 5 mg/kg of 13C-labeled urea was administered to the patient, and blood samples of 3 ml each were taken and examined after 15, 30, 60, 90, 120 and 180 min. This method has been further examined and described by Mark 3. Kim et al. in Gastroenterology 1997, 113: 31-37, W. D. Chey et al. in The American Journal of Gastroenterology, Vol. 94, 1999, pages 1522 to 1524, Alan F. Cuttler et al. in The American Journal of Gastroenterology, Vol. 94, 1999, pages 959 to 961, and has resulted in the introduction of a test by the company Metabolic Solutions Inc., Nashua, N.H. In this test, without determination of the zero value and upon administration of a high-fat test meal “Ensure”, 125 mg of 13C-urea is administered, and the 13C content of 3 ml of blood is determined after 30 min. However, due to the low accuracy and precision and due to the very high price of the necessary amount of 13C-urea and the relatively high test quantity of blood, this test was not successful economically, so that the respiration test remained the mostly used test method despite of all its disadvantages.
  • It has been the object of the invention to provide a method for the diagnosis of Helicobacter pylori infection with as low as possible an amount of 13C-urea and as low as possible a blood quantity for the examination of the 13C content, which method establishes the diagnosis of Helicobacter pylori infection more simply, more inexpensively, more accurately and more quickly.
  • This object is now achieved by removing from 0.1 to 0.6 ml of capillary blood from the finger or ear lobe of a patient or venous blood, in both cases with an empty stomach before the beginning of the test, administering an exact amount of from 10 to 50 mg of 13C-urea in aqueous solution with a pH value of 2 to 4 to the patient, again removing capillary or venous blood exactly after 10 to 15 min from the administration, and determining the 13C content of the blood samples by isotope ratio mass spectrometry (IRMS), and deducing the presence of Helicobacter pylori from the increase of the 13C values.
  • Even when 0.6 ml of capillary blood and 50 mg of 13C-urea is used, this method is clearly superior to the previous method, all the more so since the accuracy of the method is enormously increased by determining the starting value, and the method is significantly abbreviated for the patient by the removal of a second blood sample already after 10 to 15 min. In elder patients, the recovery of capillary blood sometimes involves difficulties. In such cases, the method can also be performed with the same small amount of venous blood.
  • Of critical importance in the method according to the invention is the omission of the high-fat test meal. Instead, the labeled urea is administered in an aqueous solution with a pH value of from 2 to 4. This can be done, for example, either by adjusting the aqueous solution of the labeled urea by means of a non-volatile, pharmacologically acceptable organic acid to a pH value of from 2 to 4, or by adding a pack of a solid pharmacologically acceptable organic acid to the freshly prepared solution. Citric acid has been found particularly suitable. However, in principle, other organic acids of that kind, such as ascorbic acid, are also capable of adjusting the desired pH value. It is also possible to achieve this low pH value by the use of orange juice, grapefruit juice or sour apple juice.
  • The determination of the 13C content in the blood samples can be effected, for example, by adding a strong non-volatile acid, such as phosphoric acid, which is capable to release the carbon dioxide in a gaseous form from the blood sample, so that it can be measured with an IRMS device.
  • However, it is also possible to recover serum from the blood samples, to remove high molecular weight components from the serum sample by means of suitable filters, and to determine the 13C content in the remaining liquid by a preliminary elemental analysis followed by isotope ratio mass spectrometry.
  • By comparative examinations, it was established that the detection of a Helicobacter pylori infection in a respiratory test is positive when the value of 13C in the respiratory air is about 4% above the starting values. In contrast, the method according to the invention is capable of detecting Helicobacter infections when the difference of the 13C content is as low as 2.0%. It is obvious that the substantially lower amount of the expensive 13C-urea, on the one hand, and the quickening of the time of the second sampling from 30 min to 10 min are of significant importance to both the patients and the physicians. In addition, the removal of a maximum of 0.6 ml of capillary or venous blood is significantly simpler and more convenient than the removal of 3 ml of venous blood in the test of the Metabolic Solutions Inc. As compared to this test, above all, the significantly higher accuracy and precision is of critical importance since the starting value is determined for each patient rather than using the average values, which are accompanied by considerable variations and influenced by the different foods taken up by the subjects.
  • The diagnostic kit according to the invention for performing the method preferably consists of an acidic aqueous solution having a pH value of from 2 to 4 and containing exactly from 10 to 50 mg of 13C-urea, a patient instruction sheet, two sample vessels for receiving the blood samples, and optionally a blood-sampling device. It is decisive that the kit contains an exaxt amount of 13C-urea. A kit for children may contain less than for adults in the over all range of 10 to 50 mg 13C-urea. Also the time difference between the two removals of blood should be exactly measured. Different kits, however, may be run in the over all time range of 10 to 15 min.
  • Another preferred embodiment comprises instead of the ready acidic solution a container for urea with exactly from 10 to 50 mg of 13C-urea and a pack of a solid pharmacologically acceptable organic acid, such as citric acid. Normally, 2 g of citric acid in 200 ml of water or 200 ml of orange juice, grapefruit juice, or sour apple juice is suitable for dissolving from 30 to 50 mg of 13C-urea. Especially for children, the amount of 13C-urea can be further decreased down to 10 mg.
  • The blood samples preferably are taken up in commercially available sample vessels for receiving blood samples, for example, Vacutainer®. Preferably, they may already contain the necessary amount of concentrated phosphoric acid, so that the CO2 is immediately released from the blood sample. In principle, however, it is also possible to add a strong non-volatile acid later to the sample vessel for receiving the blood sample.
  • The determination of the 13C content is then effected by IRMS directly from the gas phase. An increase of the 13C content of as low as 2% after 10 min indicates infection with Helicobacter pylori.
  • Alternatively, serum may also be withdrawn from the blood sample after a short settling period. All macromolecules and especially the lipids can be removed from this serum sample by ultrafiltration. The remaining liquid is then first subjected to elemental analysis by combustion, and the CO2 released thereby is again examined by IRMS for the isotope ratio 13C/12C. In this test method, infection with Helicobacter pylori can be detected at an increase of the 13C content of as low as from 1 to 1.5%.
  • The higher sensitivities and accuracies of the test method achieved according to the invention can be explained afterwards by the fact that the 13C content of the labeled urea is to a lesser extent diluted with other carbon sources. This dilution effect is strongest in the respiratory air test and least in the examination of serum samples from which macromolecular molecules are removed by ultrafiltration. Nevertheless, the method in which CO2 is released from the blood sample by a strong non-volatile acid and determined in the gas phase is already excellently suitable for achieving the object of the present invention.
  • When the method according to the invention is performed in practice, the blood tests are executed by the physician before and from 10 to 15 min after administration of the 13C-urea. The Vacutainers® can be collected and sent to a central laboratory where the determination of the 13C contents is effected. From these results fed-back to the physician, he can diagnose whether or not there is an infection with Helicobacter pylori.
  • In principle, all highly sensitive isotope mass spectrometers available on the market can be used for the IRMS determination; however, due to their high price, they can be set up only in central laboratories. Already for clinics, investment in such devices cannot be expected. In contrast, the collecting and analyzing of samples in central laboratories does not involve any problems today in terms of logistics and prices, and the same applies to the back transmission of analytical data to the submitting physician or the submitting clinic.
  • The same is true of the determination method in the serum from which high, molecular weight components have been removed by ultrafiltration. The preliminary elemental analysis by combustion can be performed in central laboratories without problems. The recovery of serum from capillary or venous blood and ultrafiltration can be performed without problems at least in clinics. For the actual determination of the 13C content, 20 μl of serum is sufficient and will yield telling results already for an increase of from 1 to 1.5% of 13C.

Claims (21)

1-5. (canceled)
6: A kit for diagnosing Helicobacter pylori infection in an adult by blood testing comprising:
a) an aqueous solution having a pH of 2 to 4 containing a dose of 10 to 50 mg of 13C-urea and a pharmacologically acceptable organic acid;
b) a patient instruction sheet for a blood test to diagnose Helicobacter pylori infection in an adult; and
c) two sample vessels for receiving blood samples, the sample vessels being suitable for holding a strong, non-volatile acid.
7: The diagnostic kit of claim 6 further comprising a strong, non-volatile acid in each of the two sample vessels.
8: The diagnostic kit of claim 6, wherein the organic acid is citric acid.
9: The diagnostic kit of claim 7, wherein the organic acid is citric acid.
10: The diagnostic kit of claim 6 further comprising a blood sampling device.
11: The diagnostic kit of claim 7 further comprising a blood sampling device.
12: The diagnostic kit of claim 8 further comprising a blood sampling device.
13: The diagnostic kit of claim 9 further comprising a blood sampling device.
14: A kit for diagnosing Helicobacter pylori infection in an adult by blood testing comprising:
a) a 1st container holding 10 to 50 mg of 13C-urea,
b) a 2nd container holding a solid, pharmacologically acceptable organic acid,
c) a patient instruction sheet for a blood test to diagnose Helicobacter pylori infection in an adult, and
d) two sample vessels for receiving blood samples, the sample vessels being suitable for holding a strong, non-volatile acid.
15: The diagnostic kit of claim 14, further comprising a strong, non-volatile acid in each of the two sample vessels.
16: The diagnostic kit of claim 14, wherein the organic acid is citric acid.
17: The diagnostic kit of claim 15, wherein the organic acid is citric acid.
18: The diagnostic kit of claim 14, further comprising a blood sampling device.
19: The diagnostic kit of claim 15, further comprising a blood sampling device.
20: The diagnostic kit of claim 16, further comprising a blood sampling device.
21: The diagnostic kit of claim 17, further comprising a blood sampling device.
22: A kit for diagnosing Helicobacter pylori infection in an adult by blood testing comprising:
a) an aqueous solution having a pH of 2 to 4 containing a dose of 10 to less than 50 mg of 13C-urea and a pharmacologically acceptable organic acid;
b) a patient instruction sheet for a blood test to diagnose Helicobacter pylori infection in an adult; and
c) two sample vessels for receiving blood samples, the sample vessels being suitable for holding a strong, non-volatile acid.
23: The diagnostic kit of claim 22, further comprising
d) a strong, non-volatile acid in each of the two sample vessels; and
e) a blood sampling device.
24: A kit for diagnosing Helicobacter pylori infection in an adult by blood testing comprising:
a) a 1st container holding 10 to less than 50 mg of 13C-urea,
b) a 2nd container holding a solid, pharmacologically acceptable organic acid,
d) a patient instruction sheet for a blood test to diagnose Helicobacter pylori infection in an adult, and
e) two sample vessels for receiving blood samples, the sample vessels being suitable for holding a strong, non-volatile acid.
25: The diagnostic kit of claim 24, fierier comprising:
f) a strong, nonvolatile acid in each of the two sample vessels and
g) a blood sampling device.
US11/892,163 2001-08-09 2007-08-20 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method Abandoned US20080090268A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/892,163 US20080090268A1 (en) 2001-08-09 2007-08-20 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10139299.0 2001-08-09
DE10139299 2001-08-09
US31254101P 2001-08-16 2001-08-16
US10/214,323 US7033838B2 (en) 2001-08-09 2002-08-08 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method
US11/353,126 US20060133999A1 (en) 2001-08-09 2006-02-14 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method
US11/892,163 US20080090268A1 (en) 2001-08-09 2007-08-20 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/353,126 Continuation US20060133999A1 (en) 2001-08-09 2006-02-14 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method

Publications (1)

Publication Number Publication Date
US20080090268A1 true US20080090268A1 (en) 2008-04-17

Family

ID=27214554

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/214,323 Expired - Lifetime US7033838B2 (en) 2001-08-09 2002-08-08 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method
US11/353,126 Abandoned US20060133999A1 (en) 2001-08-09 2006-02-14 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method
US11/892,163 Abandoned US20080090268A1 (en) 2001-08-09 2007-08-20 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/214,323 Expired - Lifetime US7033838B2 (en) 2001-08-09 2002-08-08 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method
US11/353,126 Abandoned US20060133999A1 (en) 2001-08-09 2006-02-14 Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method

Country Status (1)

Country Link
US (3) US7033838B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291615A1 (en) * 2009-05-15 2010-11-18 BIOMéRIEUX, INC. System and method for automatically venting and sampling a culture specimen container
US20100291619A1 (en) * 2009-05-15 2010-11-18 Biomerieux, Inc. Combined detection instrument for culture specimen containers and instrument for identification and/or characterization of a microbial agent in a sample
WO2012022428A1 (en) * 2010-08-20 2012-02-23 Cytonet Gmbh & Co. Kg Method for isolating urea while removing objectionable co2
EP2463380A1 (en) * 2010-12-07 2012-06-13 Cytonet GmbH & Co. KG Method for isolating urea by removing undesired CO2

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1553987T3 (en) * 2002-10-26 2007-12-27 Infai Inst Fuer Biomedizinisch Method for determining the emptying of the stomach with a test meal labeled with 13C
CN111257965B (en) * 2020-01-08 2021-02-26 中国科学院地质与地球物理研究所 System and method for measuring in-place of water molecule and isotope composition on lunar surface
CN114807298B (en) * 2022-05-31 2022-10-25 浙江省立同德医院(浙江省精神卫生研究院) Helicobacter pylori detect reagent box

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955054A (en) * 1998-04-29 1999-09-21 Hartmann; John F. Diagnostic assay for localizing H. pylori
US20040077965A1 (en) * 2001-11-13 2004-04-22 Photonic Biosystems, Inc. Method for diagnosis of helicobacter pylori infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5542219A (en) * 1994-01-25 1996-08-06 California Prison Industry Authority Wall panel interlock leveling device
US5542419A (en) * 1994-02-28 1996-08-06 Boston University Noninvasive method to detect gastric Helicobacter pylori
SE504902C2 (en) * 1994-11-02 1997-05-26 Diabact Ab Preparation for detection of Helicobacter pylori in the stomach
DE29613373U1 (en) 1996-08-02 1996-10-10 Biomar Diagnostic Systems Gmbh Solution for the determination of Helicobacter pylori in the human stomach and intestine ready for use in disposable bags
ES2120903B1 (en) * 1996-11-12 1999-05-16 Isomed S L METHOD AND KIT FOR THE DETECTION OF HELICOBACTER PYLORI.
US5928167A (en) * 1997-10-20 1999-07-27 Metabolic Solutions, Inc. Blood test for assessing hepatic function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955054A (en) * 1998-04-29 1999-09-21 Hartmann; John F. Diagnostic assay for localizing H. pylori
US20040077965A1 (en) * 2001-11-13 2004-04-22 Photonic Biosystems, Inc. Method for diagnosis of helicobacter pylori infection

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574219B2 (en) 2009-05-15 2017-02-21 Biomerieux, Inc. Device for sampling a specimen container
US8911987B2 (en) 2009-05-15 2014-12-16 Biomerieux, Inc System for rapid identification and/or characterization of a microbial agent in a sample
US20100291669A1 (en) * 2009-05-15 2010-11-18 Biomerieux, Inc. System for rapid identification and/or characterization of a microbial agent in a sample
US20100291618A1 (en) * 2009-05-15 2010-11-18 Biomerieux, Inc. Methods for rapid identification and/or characterization of a microbial agent in a sample
US10047387B2 (en) 2009-05-15 2018-08-14 Biomerieux, Inc. System and method for automatically venting and sampling a culture specimen container
US9856503B2 (en) 2009-05-15 2018-01-02 Biomerieux, Inc. Combined detection instrument for culture specimen containers and instrument for identification and/or characterization of a microbial agent in a sample
US20100291619A1 (en) * 2009-05-15 2010-11-18 Biomerieux, Inc. Combined detection instrument for culture specimen containers and instrument for identification and/or characterization of a microbial agent in a sample
US20100291615A1 (en) * 2009-05-15 2010-11-18 BIOMéRIEUX, INC. System and method for automatically venting and sampling a culture specimen container
WO2010132823A3 (en) * 2009-05-15 2011-06-23 Biomerieux, Inc. System and methods for rapid identification and/or characterization of a microbial agent in a sample
US8609024B2 (en) 2009-05-15 2013-12-17 Biomerieux, Inc. System and method for automatically venting and sampling a culture specimen container
US8841118B2 (en) 2009-05-15 2014-09-23 Biomerieux, Inc Combined detection instrument for culture specimen containers and instrument for identification and/or characterization of a microbial agent in a sample
KR20130110152A (en) * 2010-08-20 2013-10-08 취토넷 게엠베하 운트 코. 카게 Method for isolating urea while removing objectionable co2
WO2012022428A1 (en) * 2010-08-20 2012-02-23 Cytonet Gmbh & Co. Kg Method for isolating urea while removing objectionable co2
JP2013535972A (en) * 2010-08-20 2013-09-19 シトネット ゲーエムベーハー ウント ツェーオー．カーゲー Method for isolating urea while removing hindering CO2
US10266872B2 (en) 2010-08-20 2019-04-23 Cytonet Gmbh & Co. Kg Method for isolating urea while removing objectionable CO2
EP2463380A1 (en) * 2010-12-07 2012-06-13 Cytonet GmbH & Co. KG Method for isolating urea by removing undesired CO2

Also Published As

Publication number Publication date
US20030032081A1 (en) 2003-02-13
US7033838B2 (en) 2006-04-25
US20060133999A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
US20080090268A1 (en) Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method
Logan Urea breath tests in the management of Helicobacter pylori infection
US6491643B2 (en) Breath test analyzer
JPH02263163A (en) Test agent for measuring density of seram fructosamine in sample derived from blood sample or blood
Cheng et al. Technology development in breath microanalysis for clinical diagnosis
JP2000504423A (en) Methods and kits for detection of Helicobacter pylori
Španěl et al. What is the real utility of breath ammonia concentration measurements in medicine and physiology?
US6264913B1 (en) Non-invasive test for assessing bacterial overgrowth of the small intestine
EP1018938B1 (en) Breath test analyser
Fleming et al. Measurement of sugar probes in serum: an alternative to urine measurement in intestinal permeability testing
US6884223B2 (en) Method for detecting α-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient
Bailey Colorimetry of serum acetaminophen (paracetamol) in uremia.
CA2456546A1 (en) Method and diagnostic kit for diagnosing helicobacter pylori
CN113030327B (en) Kit for diagnosing urinary calculus based on HPLC-MS/MS and application
Oksanen et al. Accurate detection of Helicobacter pylori infection with a simplified 13C urea breath test
KR20180016510A (en) Blood analysis method and blood testing kit
EP1664771A2 (en) A method for qualitative and/or quantitative detection of polyethylene glycols in biological fluids
EP1835284B1 (en) Substrates and methods for assaying deubiquitinating enzymes activity
CN101887062A (en) Helicobacter pylori detection kit containing 13C-urea solution
RU2100010C1 (en) Method of invasive diagnosis of chelicobacteriosis in vivo
RU2229714C2 (en) Method for noninvasive diagnostics of helicobacter infection
DIANA et al. EVALUATION OF THE COLORIMETRIC CYANMETHEMOGLOBIN METHOD AND THE AUTOMATICAL HEMATOLOGY ANALYZER FOR HEMOGLOBIN ESTIMATION
McIntyre et al. Lag times between blood sampling, spinning and plasma glucose estimation
CN113533577A (en) Method for simultaneously determining blood concentration of vancomycin and aminophylline and application
JP3226943B2 (en) Liver function test kit

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION